Abstract Chloroquine and Hydroxychloroquine are drugs which have been widely used in malaria and rheumatoid arthritis respectively for over 50 years. There was anecdotal evidence of their efficacy…

Continue Reading Hydroxychloroquine for COVID-19: What is our Current State of Knowledge?

Abstract Clofazimine (CFZ), an old hydrophobic riminophenazine, has a wide range of antimycobacterial activity ranging from leprosy to nontuberculous mycobacterial diseases. CFZ has several advantages such as a…

Continue Reading Clofazimine: an old drug for never-ending diseases

Go to Publication

Continue Reading How to protect the protectors: 10 lessons to learn for doctors fighting the COVID-19 coronavirus

Abstract Background: Treatment of multidrug-resistant tuberculosis requires long-term therapy with a combination of multiple second-line drugs. These drugs are associated with numerous adverse events that can cause severe…

Continue Reading Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis

Go to Publication

Continue Reading Challenging the management of drug-resistant tuberculosis – Authors’ reply

Abstract Tuberculosis is one of the top ten causes of death and the leading cause from a single infectious agent. Drug-resistant Tuberculosis continues to be a public health…

Continue Reading From pulmonary susceptible tuberculosis to extensively drug resistant tuberculosis: An interesting case report of a young Indian girl

Abstract The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians…

Continue Reading MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network

Go to actual article

Continue Reading Coronavirus task force’s SOS to CM Uddhav Thackeray, Union government